Beyond Weight Loss: GLP-1s for Heart, Liver and Sleep Apnea

Most people meet a GLP-1 medication as a weight tool. Then a quieter story shows up in the trial data. The same medicines that help with weight have now earned separate FDA approvals for the heart, the liver, and a sleep disorder you might not connect to either one. That second story is the one your physician may care about most. Here is what the labels actually say.

A GLP-1 "beyond weight loss" means an FDA-approved use that is not about the scale. As of 2026, Wegovy® (semaglutide) is approved to lower major cardiovascular event risk and to treat a serious liver disease called MASH. Zepbound® (tirzepatide) is approved for moderate to severe obstructive sleep apnea in adults with obesity. Individual results vary; sources are dated below.

A GLP-1 earning a heart approval is a real shift. In 2024, the FDA approved Wegovy to reduce the risk of major cardiovascular events in adults who have known heart disease and either obesity or overweight. That is not a weight claim. It is a heart-attack-and-stroke claim, and it stands on a large trial.

The approval rests on the SELECT trial. Researchers followed more than 17,000 adults who had heart disease and were overweight or had obesity, but did not have diabetes. People on semaglutide had about a 20% lower rate of major cardiovascular events, meaning cardiovascular death, heart attack, or stroke, compared with placebo. ¹ The result was published in the New England Journal of Medicine in 2023. Individual results vary.

In 2025, the FDA gave Wegovy an accelerated approval to treat a liver disease called noncirrhotic MASH, short for metabolic dysfunction-associated steatohepatitis, in adults with moderate to advanced liver fibrosis. ² In plain terms, that is a scarring liver condition tied to metabolic health. It is not a weight claim either.

Here is the part that matters most. These three uses are FDA-approved with real trials behind them. Plenty of other "GLP-1 fixes everything" claims floating around online are not. Some are early research. Some are pure hope. An approved use has a label, a population, and a trial. Anything else is your physician's call, made for you, not a headline.

This is where the brand you choose earns trust or loses it. A good provider does three things here. It confirms a diagnosis before claiming a "beyond weight loss" benefit, instead of implying every patient gets the heart or liver upside. It tells you whether you are getting a branded, FDA-approved product or a compounded medication, and what that means for these specific uses. And it keeps a physician in the loop to manage your treatment over time, not just at sign-up. If a brand blurs any of those three, treat that as a signal.

Know what product you are on. Ask whether you are getting a branded, FDA-approved medicine or a compounded one, and what that means for these specific approved uses. A clear answer is the baseline.